European Medical Journal Cardiology (Feb 2022)

Idarucizumab in Emergent Pericardiocentesis: A Case Report of Dabigatran-Induced Haemopericardium and Cardiac Tamponade

  • Elisabetta Palmerini,
  • Francesco De Tommasi,
  • Tamara Taddei,
  • Stefano Amidei,
  • Giovanni Falsini

DOI
https://doi.org/10.33590/emjcardiol/21-00165

Abstract

Read online

Haemopericardium has rarely been described in association with the use of a non-vitamin K antagonist oral anticoagulant. Cardiac tamponade is a life-threatening condition that usually requires urgent pericardiocentesis. Here, the authors report a case of haemopericardium with cardiac tamponade during dabigatran therapy for atrial fibrillation in a patient with chronic coronary syndrome, treated effectively with reversal agent idarucizimab before pericardiocentesis. To the authors’ knowledge, this is only the third report of dabigatran-induced haemopericardium.